Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab SC in First-Line Advanced or Metastatic NSCLC
NCT06091943Phase 1Completed
- Sponsor
- BeiGene
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of tislelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by BeiGene. Primary endpoints: Area under the concentration-time curve at 3.5 months, Concentration at the end of dosing interval at 3.5 months and 5 more. Started Nov 2023; status: completed.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06091943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091943.